100 years after the discovery of a bacterial 'endotoxin', 50 years after the introduction of antibiotics and 25 years after the routine use of intensive care units to support septic shock patients, Gram-negative infections continue to account for significant morbidity and mortality. In the coming decade, basic research on the structure/function of LPS, the cytokine cascade, and receptor-mediated intracellular signalling responses to LPS and cytokines will provide a greater understanding of the molecular, cellular and systemic responses to endotoxin and infection. New therapeutic agents now emerging from research, and better designed clinical trials to assess those agents will contribute to the next significant decline in sepsis- and shock-related morbidity and mortality. This article summarizes the findings of a workshop convened at the National Institutes of Health (NIH) to examine current research on endotoxin and Gram-negative septic shock.
Get full access to this article
View all access options for this article.
References
1.
Morrison D.C. , Ulevitch R.J.The interaction of bacterial endotoxins with cellular and humoral mediation systems. Am J Pathol1978; 92: 527-618.
2.
Kirikae T., Lei M-G., Chen T-Y., Morrison D.C.Interaction of endotoxins with membranes and membrane receptors. In: Brigham K L, ed. Endotoxin and the lungs, New York: Marcel Dekker , 1994. In press.
3.
Vogel S.N., Hogan M.M.The role of cytokines in endotoxin-mediated responses. In: Oppenheim J J, Shevach E , eds. Immunophysiology: roles of cells and cytokines in immunity and inflammation1990: 238-258.
4.
Centers for Disease Control1990. Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987. Morbid Mortal Weekly Report; 39: 31-34.
5.
Takada H., Kotuni S.Structure function relationships of lipid A. In: Morrison D C, Ryan J L, eds. Bacterial endotoxic lipopolysaccharides I. Boca Raton: CRC Press, 1992: 107-134.
6.
Seydel V., Brandenburg K.Supramolecular structure of lipopolysaccharide and lipid A. In: Morrison D C, Ryan J L, eds. Bacterial endotoxic lipopolysaccharides I . Boca Raton: CRC Press, 1992: 225-250.
7.
Haeffner-Cavaillon N., Caroff, M., Cavaillon J.M.Interleukin-1 induction by lipopolysaccharides structural requirements of the 3-deoxy-D-manno-2-octulosonic acid (KDO). Mol Immunol1989; 26: 485-494.
8.
Luderitz T., Brandenburg K., Seydel V., Roth A., Galanos C., Rietschel E.Structural and physiochemical requirements of endotoxins for the activation of arachidonic acid metabolism in mouse peritoneal macrophages in vitro. Eur J Biochem1989; 179: 11-16.
9.
Anon.A nasty shock from antibiotics?Lancet1985 ; ii: 594.
10.
Hurley J.C.Antibiotic-induced release of endotoxin: A reappraisal . Clin Infect Dis1992; 15: 840-854.
11.
Jackson J.J. , Kropp H.β-lactam antibiotic-induced release of free endotoxin: In vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis1992; 165: 1033-1041.
12.
Bucklin S.E., Morrison D.C.Contribution of antibiotic-derived endotoxin to lethality in experimental bacteremia and sepsis. Abstr 33rd ICAAC, American Society for Microbiology Publications, Washington DC, 1993: 379.
13.
Ulevitch R.J.Recognition of bacterial endotoxins by receptor-dependent mechanisms. Adv Immunol1993; 53: 267-289.
14.
Wright S.Multiple receptors for endotoxin. Curr Opin Immunol1991; 91: 83-90.
15.
Lee J-D., Kravchenko V., Kirkland T.N. et al. GPI-anchored or integral membrane forms of CD14 mediate identical cellular responses to endotoxin. Proc Natl Acad Sci USA1993; 90: 9930-9934.
16.
Pugin J., Schurer-Maly C C., Leturcq D., Moriarty A., Ulevitch R J., Tobias P S.Lipopolysaccharide (LPS) activation of human endothelial and epithelial cells is mediated by LPS binding protein and soluble CD14. Proc Natl Acad Sci USA1993; 90: 2744-2748.
17.
Pugin J., Lee J-D., Tobias P.S., Ulevitch R.J.A critical role for myeloid cells and CD14 in endotoxin-induced endothelial cell activation. J Exp Med1993; 178: 2193-2200.
18.
Han J., Lee J-D., Tobias P.S., Ulevitch R.J.Bacterial lipopolysaccharide induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14. J Biol Chem1993; 268: 25009-25014.
19.
Weinstein S.L. , June C.H., DeFranco A.L.Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14. J Immunol1993; 151: 3829-3839.
20.
Dinarello C.A. , Gelfand J.A., Wolff S.M.Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA1993; 269: 1829-1835.
21.
Okusawa S., Gelfand J.A., Ikejima T., Connolly R.J., Dinarello C.A.Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest1988; 81: 1162-1172.
22.
Neta R., Sayers T., Oppenheim J.J.Relationship of tumor necrosis factor to interleukins. In: Vilcek J, Aggarwal B, eds. Tumor necrosis factor: structure function and mechanism of action . New York: Marcel Dekker, 1991: 499-566.
23.
Casey L.C., Balk R.A., Bone R.C.Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med1993 ; 119: 771-778.
24.
Fisher C J J, Dhainaut J.F., Pribble J., Knaus W., Catalano M.A.A study evaluating the efficacy of human recombinant interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: preliminary results from a phase III multicenter trial. 13th International Symposium Intensive CareEmergency Medicine ; Brussels. 1993 (abstr).
25.
Bautista A.P. , Deaciuc I.V., Jaeschke H., Spolarics Z., Spitzer J.J.Hepatic responses to bacterial endotoxin (LPS). In: Schlag G , Redl H, eds. Pathophysiology of shock, sepsis, and organ failure. Berlin: Springer-Verlag , 1993: 915-934.
Jaeschke H. , Bautista A.P., Spolarics Z., Spitzer J.J.Superoxide anion generation by neutrophils and Kupffer cells during in vivo reperfusion after hepatic ischemia in rats . J Leukoc Biol1992; 52: 377-382.
28.
Bautista A.P. , Meszaros K., Bojta J., Spitzer J.J.Superoxide anion generation in the liver during the early stage of endotoxemia in rats . J Leukoc Biol1990; 48: 123-128.
29.
Nelson S., Bagby G.J., Bainton B.G. et al. Compartmentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis1989; 159: 189-194.
30.
Deaciuc I.V. , McDonough K.H., Bagby G.J., Spitzer J.J.Alcohol consumption in rats potentiates the deleterious effect of gram-negative sepsis on hepatic hyaluronan uptake . Alcohol Clin Exp Res1993 ; 17: 1002-1008.
31.
Hyde S.R., McCallum R.E.Lipopolysaccharide-tumor necrosis factor glucocorticoid interactions during cecal ligation and puncture-induced sepsis in mature vs senescent mice . Infect Immun1992; 60: 976-982.
32.
Vogel S.N.The Lps gene: insights into the genetic and molecular basis of LPS responsiveness and macrophage differentiation. In: Beutler B, ed. Tumor necrosis factors: the molecules and their emerging role in medicine. New York: Raven Press, 1992: 485-513.
33.
Madonna G.S. , Peterson J., Ribi E., Vogel S.N.Early phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A. Infect Immun1986; 52: 6-11.
34.
Virca G.D., S. Kim, Glaser K., Ulevitch R.Lipopolysaccharide induces hyporesponsiveness to its own action in RAW 264.7 cells. J Biol Chem1989; 264: 21951-21956.
35.
Henricson B.E. , Manthey C.L., Pereva P.Y., Hamilton T.A., Vogel S.N.Dissociation of lipopolysaccharide (LPS) inducible gene expression in murine macrophages preheated with smooth LPS versus monophosphoryl lipid A. Infect Immun1993; 61: 2325-2333.
36.
Luchi M., Munford R.S.Binding, internalization, and deacylation of bacterial lipopolysaccharides by human neutrophils. J Immunol1993; 151: 959-969.
37.
Duncan R.L. Jr, Hoffman J., Tesh V.L., Morrison D.C.Immunologic activity of lipopolysaccharides released from macrophages after the uptake of intact E. coli in vitro. J Immunol1986 ; 136: 2924-2929.
38.
Granfors K. , Jalkanen S., Von Essen R et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. New Engl J Med1989; 320: 216-221.
39.
Elsbach P., Goldman J., Patriarca P.Phospholipid metabolism by phagocytic cells. VI. Observations on the fate of phospholipids of granulocytes and ingested Escherichia coli during phagocytosis . Biochim Biophys Acta1972; 280: 33-44.
40.
Rabinowitz S., Hortsmann H., Gordon S., Griffiths G.Immunocytochemical characterization of the endocytic and phagolysosomal compartments in peritoneal macrophages. J Cell Biol1992; 116: 95-112.
41.
Pohlman T.H. , Munford R.S., Harlan J.M.Deacylated lipopolysaccharide inhibits neutrophil adherence to endothelium induced by lipopolysaccharide in vitro. J Exp Med1987; 165: 1393-1402.
42.
Pollack M.Specificity and function of lipopolysaccharide antibodies. In: Ryan J L, Morrison D C, eds. Bacterial endotoxic lipopolysaccharides. Vol. II. Immunopharmacology and pathophysiology. Boca Raton : CRC Press, 1992: 347-374.
43.
Pollack M., Chia J K S, Koles N.L., Miller M., Guelde G.Specificity and cross-reactivity of monoclonal antibodies reactive with the core lipid A regions of bacterial lipopolysaccharide. J Infect Dis1989; 159: 168-188.
44.
Oishi K., Koles N.L., Guelde G., Pollack M.Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli 0111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. J Infect Dis1992; 165: 34-45.
45.
Krieger J.I. , Fletcher R.C., Siegel S.A. et al. Human anti-endotoxin antibody HA-1A mediates complement-dependent binding of Escherichia coli J5 lipopolysaccharide to complement receptor type 1 of human erythrocytes and neutrophils. J Infect Dis1993; 167: 865-875.
46.
Pollack M., Koles N.L., Evans M.E. et al. Antibacterial and anti-endotoxic actions and interactions of lipopolysaccharide antibodies and complement. In: Levin J, Munford R S, Alving C R, Stütz P L, eds. Bacterial endotoxin: recognition and effector mechanisms. Amsterdam: Elsevier, 1993: 113-122.
47.
Heumann D., Gallay P., Barras C. et al. Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretionin human peripheral blood monocytes. J Immunol1992; 148: 3505-3512.
48.
Schreiber J.R. , Cooper L J N, Diehn S. et al. Variable region-identical monoclonal antibodies of different IgG subclass directed to Pseudomonas aeruginosa lipopolysaccharide o-specific side chain function differently. J Infect Dis1993; 167: 221-226.
49.
Field S., Pollack M., Motrison D.C.Development of an anti-idiotype monoclonal antibody mimicking the structure of lipopolysaccharide (LPS) inner-core determinants. Microb Pathog1993; 15: 103-120.
50.
Cross A.S., Opal S.M., Palardy J.E., Bodmer M.W., Sadoff J.C.The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J. Infect Dis1993; 167: 112-118.
51.
Suffredini A.F. , Fromm R.E., Parker M.M. et al. The cardiovascular response of normal humans to administration of endotoxin. N Engl J Med1989; 321: 280-287.
52.
Natanson C. , Eichenholz P.W., Danner R.L. et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock . J Exp Med1989; 169: 823-932.
53.
Natanson C. , Danner R.L., Elin R.J. et al. Role of endotoxemia in cardiovascular dysfunction and mortality: E. coli and S. aureus challenges in a canine model of human septic shock. J Clin Invest1989; 83: 243-251.
54.
Danner R.L., Natanson C. Endotoxin: a mediator of and potential therapeutic target for septic shock. In: Moss J, ed. Handbook for natural toxins, vol. 8, Microbial toxins. New York: Marcel Dekker, 1994. in press.
55.
Danner R.L. , Elin R.J., Hosseini J.M. et al. Endotoxemia in human septic shock . Chest1991; 99: 169-176.
56.
Greisman S.E. , Hornick R.B., Wagner H.N. Jr, Woodward W.E., Woodward T.E.The role of endotoxin during typhoid fever and tularemia in man. IV. The integrity of the endotoxin tolerance mechanisms during infection. J Clin Invest1969; 48: 613-629.
57.
McCabe W.R., Olans R.N.Shock in gram-negative bacteremia: predisposing factors, pathophysiology, and treatment. In: Remington J S, Swartz M N, eds. Current clinical topics in infectious disease, Vol. 2. New York: McGraw Hill, 1981: 121-150.
58.
Adi S., Pollock A.S., Shigenaga J.K., Moser A.H., Feingold K.R., Grunfeld C.Role for monokines in the metabolic effects of endotoxin. J Clin Invest1992; 89: 1603-1609.
59.
Parrillo J.E.Pathogenic mechanisms of septic shock. New Engl J Med1993; 328: 1471-1477.
60.
Bone R.C.Gram-negative sepsis: a dilemma of modem medicine. Clin Microbiol Rev1993; 6: 57-68.
